Novel strategies for relapsed/refractory DLBCL; navigating the immunotherapy era in aggressive lymphoma

References

• Wild CP, Weiderpass E, Stewart BW. World cancer report: cancer research for cancer prevention; 2020. https://publications.iarc.fr/586.
   Google Scholar
• McKelvey EM, Gottlieb JA, Wilson HE, et al. Hydroxyldaunomycin (adriamycin) combination chemotherapy in malignant lymphoma. Cancer. 1976;38(4):1484–1493.
   PubMed Web of Science ®Google Scholar
• Gottlieb JA, Gutterman JU, McCredie KB, et al. Chemotherapy of malignant lymphoma with adriamycin. Cancer Res. 1973;33(11):3024–3028.
   PubMed Web of Science ®Google Scholar
• Westin J, Fayad L. Beyond R-CHOP and the IPI in large-cell lymphoma: molecular markers as an opportunity for stratification. Curr Hematol Malig Rep. 2009;4(4):218–224.
   PubMedGoogle Scholar
• Fisher RI, Gaynor ER, Dahlberg S, et al. Comparison of a standard regimen (CHOP) with three intensive chemotherapy regimens for advanced non-Hodgkin's lymphoma. N Engl J Med. 1993;328(14):1002–1006.
   PubMed Web of Science ®Google Scholar
• Coiffier B, Haioun C, Ketterer N, et al. Rituximab (anti-CD20 monoclonal antibody) for the treatment of patients with relapsing or refractory aggressive lymphoma: a multicenter phase II study. Blood. 1998;92(6):1927–1932.
   PubMed Web of Science ®Google Scholar
• Vose JM, Link BK, Grossbard ML, et al. Phase II study of rituximab in combination with chop chemotherapy in patients with previously untreated, aggressive non-Hodgkin's lymphoma. J Clin Oncol. 2001;19(2):389–397.
   PubMed Web of Science ®Google Scholar
• Coiffier B, Lepage E, Briere J, et al. CHOP chemotherapy plus rituximab compared with CHOP alone in elderly patients with diffuse large-B-cell lymphoma. N Engl J Med. 2002;346(4):235–242.
   PubMed Web of Science ®Google Scholar
• Sehn LH, Martelli M, Trněný M, et al. A randomized, open-label, phase III study of obinutuzumab or rituximab plus CHOP in patients with previously untreated diffuse large B-Cell lymphoma: final analysis of GOYA. J Hematol Oncol. 2020;13(1):71.
   PubMed Web of Science ®Google Scholar
• Salles G, Duell J, González Barca E, et al. Tafasitamab plus lenalidomide in relapsed or refractory diffuse large B-cell lymphoma (L-MIND): a multicentre, prospective, single-arm, phase 2 study. Lancet Oncol. 2020;21(7):978–988.
   PubMed Web of Science ®Google Scholar
• Duell J, Maddocks KJ, González-Barca E, et al. Long-term outcomes from the phase II L-MIND study of tafasitamab (MOR208) plus lenalidomide in patients with relapsed or refractory diffuse large B-cell lymphoma. Haematologica. 2021;106(9):2417–2426.
   PubMed Web of Science ®Google Scholar
• Sehn LH, Herrera AF, Flowers CR, et al. Polatuzumab vedotin in relapsed or refractory diffuse large B-Cell lymphoma. J Clin Oncol. 2020;38(2):155–165.
   PubMed Web of Science ®Google Scholar
• Jacobsen ED, Sharman JP, Oki Y, et al. Brentuximab vedotin demonstrates objective responses in a phase 2 study of relapsed/refractory DLBCL with variable CD30 expression. Blood. 2015;125(9):1394–1402.
   PubMed Web of Science ®Google Scholar
• Caimi PF, Ai W, Alderuccio JP, et al. Loncastuximab tesirine in relapsed or refractory diffuse large B-cell lymphoma (LOTIS-2): a multicentre, open-label, single-arm, phase 2 trial. Lancet Oncol. 2021;22(6):790–800.
   PubMed Web of Science ®Google Scholar
• Neelapu SS, Locke FL, Bartlett NL, et al. Axicabtagene ciloleucel CAR T-cell therapy in refractory large B-Cell lymphoma. N Engl J Med. 2017;377(26):2531–2544.
   PubMed Web of Science ®Google Scholar
• Locke FL, Miklos DB, Jacobson C, et al. Primary analysis of ZUMA-7: a phase 3 randomized trial of axicabtagene ciloleucel (Axi-Cel) versus standard-of-Care therapy in patients with relapsed/refractory large B-Cell lymphoma. Blood. 2021;138(Supplement 1):2–2.
   Google Scholar
• Locke FL, Miklos DB, Jacobson CA, et al. Axicabtagene ciloleucel as second-line therapy for large B-Cell lymphoma. New Eng J Med. 2021. 10.1056/NEJMoa2116133.
   PubMed Web of Science ®Google Scholar
• Neelapu SS, Dickinson M, Munoz J, et al. Primary analysis of ZUMA-12: a phase 2 study of axicabtagene ciloleucel (Axi-Cel) as first-line therapy in patients with high-risk large B-cell lymphoma (LBCL). Blood. 2021;138(Supplement 1):739–739.
   PubMedGoogle Scholar
• Schuster SJ, Tam CS, Borchmann P, et al. Long-term clinical outcomes of tisagenlecleucel in patients with relapsed or refractory aggressive B-cell lymphomas (JULIET): a multicentre, open-label, single-arm, phase 2 study. Lancet Oncol. 2021;22(10):1403–1415.
   PubMed Web of Science ®Google Scholar
• Bishop MR, Dickinson M, Purtill D, et al. Second-Line tisagenlecleucel or standard care in aggressive B-Cell lymphoma. New Eng J Med. 2021. 10.1056/NEJMoa1804980.
   Web of Science ®Google Scholar
• Kamdar M, Solomon SR, Arnason JE, et al. Lisocabtagene maraleucel (liso-cel), a CD19-Directed chimeric antigen receptor (CAR) T cell therapy, versus standard of care (SOC) with salvage chemotherapy (CT) followed by autologous stem cell transplantation (ASCT) as Second-Line (2L) treatment in patients (pts) with relapsed or refractory (R/R) large B-Cell lymphoma (LBCL): results from the randomized phase 3 transform study. Blood. 2021;138(Supplement 1):91–91.
   PubMedGoogle Scholar
• Armand P, Rodig S, Melnichenko V, et al. Pembrolizumab in relapsed or refractory primary mediastinal large B-cell lymphoma. J Clin Oncol. 2019;37(34):3291–3299.
   PubMed Web of Science ®Google Scholar
• Zinzani PL, Santoro A, Gritti G, et al. Nivolumab combined with brentuximab vedotin for relapsed/refractory primary mediastinal large B-cell lymphoma: efficacy and safety from the phase II CheckMate 436 study. J Clin Oncol. 2019;37(33):3081–3089.
   PubMed Web of Science ®Google Scholar
• Budde LE, Assouline S, Sehn LH, et al. Single-Agent mosunetuzumab shows durable complete responses in patients with relapsed or refractory B-cell lymphomas: phase I dose-escalation study. J Clin Oncol. 2021;Jco2100931. 10.1200/JCO.21.00931.
   Web of Science ®Google Scholar
• Hutchings M, Morschhauser F, Iacoboni G, et al. Glofitamab, a novel, bivalent CD20-Targeting T-cell-engaging bispecific antibody, induces durable complete remissions in relapsed or refractory B-cell lymphoma: a phase I trial. J Clin Oncol. 2021;39(18):1959–1970.
   PubMed Web of Science ®Google Scholar
• Hutchings M, Sureda A, Terol MJ, et al. Glofitamab (glofit) in combination with polatuzumab vedotin (pola): phase Ib/II preliminary data support manageable safety and encouraging efficacy in relapsed/refractory (R/R) diffuse large B-Cell lymphoma (DLBCL). Blood. 2021;138(Supplement 1):525–525.
   Google Scholar
• Tilly H, Morschhauser F, Sehn LH, et al. Polatuzumab vedotin in previously untreated diffuse large B-Cell lymphoma. N Engl J Med. 2022;386(4):351–363.
   PubMed Web of Science ®Google Scholar
• Hu Y, Zhang Y, Zhao H, et al. CD19/CD22 dual-targeted chimeric antigen receptor T-cell therapy for relapsed/refractory aggressive B-cell lymphoma: a safety and efficacy study. Blood. 2020;136(Supplement 1):34–34.
   Google Scholar
• Tong C, Zhang Y, Liu Y, et al. Optimized tandem CD19/CD20 CAR-engineered T cells in refractory/relapsed B-cell lymphoma. Blood. 2020;136(14):1632–1644.
   PubMed Web of Science ®Google Scholar
• Abramson JS, Palomba ML, Gordon LI, et al. Lisocabtagene maraleucel for patients with relapsed or refractory large B-cell lymphomas (TRANSCEND NHL 001): a multicentre seamless design study. Lancet. 2020;396(10254):839–852.
   PubMed Web of Science ®Google Scholar
• Schuster SJ, Bishop MR, Tam CS, et al. Tisagenlecleucel in adult relapsed or refractory diffuse large B-Cell lymphoma. N Engl J Med. 2019;380(1):45–56.
   PubMed Web of Science ®Google Scholar
• Locke FL, Ghobadi A, Jacobson CA, et al. Long-term safety and activity of axicabtagene ciloleucel in refractory large B-cell lymphoma (ZUMA-1): a single-arm, multicentre, phase 1-2 trial. Lancet Oncol. 2019;20(1):31–42.
   PubMed Web of Science ®Google Scholar
• Jacobson C, Locke FL, Ghobadi A, et al. Long-Term (≥4 year and ≥5 year) overall survival (OS) by 12- and 24-Month Event-Free survival (EFS): an updated analysis of ZUMA-1, the pivotal study of axicabtagene ciloleucel (Axi-Cel) in patients (pts) with refractory large B-Cell lymphoma (LBCL). Blood. 2021;138(Supplement 1):1764–1764.
   Google Scholar
• Maziarz RT, Waller EK, Jaeger U, et al. Patient-reported long-term quality of life after tisagenlecleucel in relapsed/refractory diffuse large B-cell lymphoma. Blood Adv. 2020;4(4):629–637.
   PubMed Web of Science ®Google Scholar
• Abramson JS, Palomba ML, Gordon LI, et al. Two-Year follow-up of transcend NHL 001, a multicenter phase 1 study of lisocabtagene maraleucel (liso-cel) in relapsed or refractory (R/R) large B-Cell lymphomas (LBCL). Blood. 2021;138(Supplement 1):2840–2840.
   Google Scholar
• Oluwole OO, Bishop MR, Gisselbrecht C, et al. ZUMA-7: a phase 3 randomized trial of axicabtagene ciloleucel (Axi-Cel) versus standard-of-care (SOC) therapy in patients with relapsed/refractory diffuse large B cell lymphoma (R/R DLBCL). J Clin Oncol. 2018;36(15_suppl):TPS7585–TPS.
   Web of Science ®Google Scholar
• Albinger N, Hartmann J, Ullrich E. Current status and perspective of CAR-T and CAR-NK cell therapy trials in Germany. Gene Ther. 2021;28(9):513–527.
   PubMed Web of Science ®Google Scholar
• Nastoupil LJ, Jain MD, Feng L, et al. Standard-of-Care axicabtagene ciloleucel for relapsed or refractory large B-cell lymphoma: results from the US lymphoma CAR T consortium. J Clin Oncol. 2020;38(27):3119–3128.
   PubMed Web of Science ®Google Scholar
• Liang A, Ye S, Li P, et al. Safety and efficacy of a novel anti-CD20 chimeric antigen receptor (CAR)-T cell therapy in relapsed/refractory (r/r) B-cell non-Hodgkin lymphoma (B-NHL) patients after failing CD19 CAR-T therapy. J Clin Oncol. 2021;39(15_suppl):2508–2508.
   Google Scholar
• Vercellino L, Di Blasi R, Kanoun S, et al. Predictive factors of early progression after CAR T-cell therapy in relapsed/refractory diffuse large B-cell lymphoma. Blood Adv. 2020;4(22):5607–5615.
   PubMed Web of Science ®Google Scholar
• Locke FL, Rossi JM, Neelapu SS, et al. Tumor burden, inflammation, and product attributes determine outcomes of axicabtagene ciloleucel in large B-cell lymphoma. Blood Adv. 2020;4(19):4898–4911.
   PubMed Web of Science ®Google Scholar
• Neelapu SS, Dickinson M, Ulrickson ML, et al. Interim analysis of ZUMA-12: a phase 2 study of axicabtagene ciloleucel (Axi-Cel) as first-line therapy in patients (pts) with High-Risk large B cell lymphoma (LBCL). Blood. 2020;136(Supplement 1):49–49.
   Google Scholar
• Frank MJ, Hossain NM, Bukhari A, et al. Monitoring of circulating tumor DNA improves early relapse detection after axicabtagene ciloleucel infusion in large B-Cell lymphoma: results of a prospective multi-institutional trial. J Clin Oncol. 2021;39(27):3034–3043.
   PubMed Web of Science ®Google Scholar
• Deng Q, Han G, Puebla-Osorio N, et al. Characteristics of anti-CD19 CAR T cell infusion products associated with efficacy and toxicity in patients with large B cell lymphomas. Nat Med. 2020;26(12):1878–1887.
   PubMed Web of Science ®Google Scholar
• Li AM, Hucks GE, Dinofia AM, et al. Checkpoint inhibitors augment CD19-Directed chimeric antigen receptor (CAR) T cell therapy in relapsed B-cell acute lymphoblastic leukemia. Blood. 2018;132(Supplement 1):556–556.
   Google Scholar
• Jain MD, Zhao H, Wang X, et al. Tumor interferon signaling and suppressive myeloid cells are associated with CAR T-cell failure in large B-cell lymphoma. Blood. 2021;137(19):2621–2633.
   PubMed Web of Science ®Google Scholar
• Fraietta JA, Beckwith KA, Patel PR, et al. Ibrutinib enhances chimeric antigen receptor T-cell engraftment and efficacy in leukemia. Blood. 2016;127(9):1117–1127.
   PubMed Web of Science ®Google Scholar
• Lemoine J, Morin F, Di Blasi R, et al. Lenalidomide exposure at time of CAR T-cells expansion enhances response of refractory/relapsed aggressive large B-Cell lymphomas. Blood. 2021;138(Supplement 1):1433–1433.
   Google Scholar
• Hanahan D, Weinberg RA. Hallmarks of cancer: the next generation. Cell. 2011;144(5):646–674.
   PubMed Web of Science ®Google Scholar
• Kubli SP, Berger T, Araujo DV, et al. Beyond immune checkpoint blockade: emerging immunological strategies. Nat Rev Drug Discov. 2021;20(12):899–919.
   PubMed Web of Science ®Google Scholar
• Sharpe AH, Pauken KE. The diverse functions of the PD1 inhibitory pathway. Nat Rev Immunol. 2018;18(3):153–167.
   PubMed Web of Science ®Google Scholar
• Le DT, Uram JN, Wang H, et al. PD-1 blockade in tumors with mismatch-repair deficiency. N Engl J Med. 2015;372(26):2509–2520.
   PubMed Web of Science ®Google Scholar
• Sun L, Zhang L, Yu J, et al. Clinical efficacy and safety of anti-PD-1/PD-L1 inhibitors for the treatment of advanced or metastatic cancer: a systematic review and meta-analysis. Sci Rep. 2020;10(1):2083.
   PubMed Web of Science ®Google Scholar
• Griffin GK, Weirather JL, Roemer MGM, et al. Spatial signatures identify immune escape via PD-1 as a defining feature of T-cell/histiocyte-rich large B-cell lymphoma. Blood. 2021;137(10):1353–1364.
   PubMed Web of Science ®Google Scholar
• Wang Y, Wenzl K, Manske MK, et al. Amplification of 9p24.1 in diffuse large B-cell lymphoma identifies a unique subset of cases that resemble primary mediastinal large B-cell lymphoma. Blood Cancer J. 2019;9(9):73.
   PubMedGoogle Scholar
• Chong EA, Melenhorst JJ, Svoboda J, et al. Phase I/II study of pembrolizumab for progressive diffuse large B cell lymphoma after anti-CD19 directed chimeric antigen receptor modified T cell therapy. Blood. 2017;130(Supplement 1):4121.
   Google Scholar
• Jacobson CA, Westin JR, Miklos DB, et al. Abstract CT055: Phase 1/2 primary analysis of ZUMA-6: Axicabtagene ciloleucel (Axi-Cel) in combination with atezolizumab (atezo) for the treatment of patients (pts) with refractory diffuse large B cell lymphoma (DLBCL). Cancer Research. 2020. 80(16 Supplement):CT055–CT.
   Google Scholar
• Godfrey J, Tumuluru S, Bao R, et al. PD-L1 gene alterations identify a subset of diffuse large B-cell lymphoma harboring a T-cell-inflamed phenotype. Blood. 2019;133(21):2279–2290.
   PubMed Web of Science ®Google Scholar
• Smith SD, Till BG, Shadman MS, et al. Pembrolizumab with R-CHOP in previously untreated diffuse large B-cell lymphoma: potential for biomarker driven therapy. Br J Haematol. 2020;189(6):1119–1126.
   PubMed Web of Science ®Google Scholar
• Hawkes EA, Chong G, Smith C, et al. Safety and efficacy of induction and maintenance avelumab plus R-CHOP in patients with diffuse large B-Cell lymphoma (DLBCL): analysis of the phase II Avr-CHOP study. Blood. 2020;136(Supplement 1):43–44.
   Google Scholar
• Nowakowski GS, Willenbacher W, Greil R, et al. Safety and efficacy of PD-L1 inhibitor durvalumab with R-CHOP or R2-CHOP in subjects with previously untreated, high-risk DLBCL. J Clin Oncol. 2019;37(15_suppl):7520–7520.
   Web of Science ®Google Scholar
• Younes A, Burke JM, Cheson BD, et al. Safety and efficacy of atezolizumab in combination with rituximab plus CHOP in previously untreated patients with diffuse large B-Cell lymphoma (DLBCL): updated analysis of a phase I/II study. Blood. 2019;134(Supplement_1):2874–2874.
   Google Scholar
• Jaeger U, Worel N, McGuirk JP, et al. Portia: a phase 1b study evaluating safety and efficacy of tisagenlecleucel and pembrolizumab in patients with relapsed/refractory diffuse large B-Cell lymphoma. Blood. 2019;134(Supplement_1):5325–5325.
   Google Scholar
• Keane C, Law SC, Gould C, et al. LAG3: a novel immune checkpoint expressed by multiple lymphocyte subsets in diffuse large B-cell lymphoma. Blood Adv. 2020;4(7):1367–1377.
   PubMed Web of Science ®Google Scholar
• Roussel M, Le K-S, Granier C, et al. Functional characterization of PD1 + TIM3+ tumor-infiltrating T cells in DLBCL and effects of PD1 or TIM3 blockade. Blood Adv. 2021;5(7):1816–1829.
   PubMed Web of Science ®Google Scholar
• Josefsson SE, Beiske K, Blaker YN, et al. TIGIT and PD-1 mark intratumoral T cells with reduced effector function in B-cell Non-Hodgkin lymphoma. Cancer Immunol Res. 2019;7(3):355–362.
   PubMed Web of Science ®Google Scholar
• Labrijn AF, Janmaat ML, Reichert JM, et al. Bispecific antibodies: a mechanistic review of the pipeline. Nat Rev Drug Discov. 2019;18(8):585–608.
   PubMed Web of Science ®Google Scholar
• Olszewski AJ, Avigdor A, Babu S, et al. Single-agent mosunetuzumab is a promising safe and efficacious chemotherapy-free regimen for elderly/unfit patients with previously untreated diffuse large B-cell lymphoma. Blood. 2020;136(Supplement 1):43–45.
   Google Scholar
• Phillips TJ, Olszewski AJ, Munoz J, et al. Mosunetuzumab, a novel CD20/CD3 bispecific antibody, in combination with CHOP confers high response rates in patients with diffuse large B-Cell lymphoma. Blood. 2020;136(Supplement 1):37–38.
   Google Scholar
• Schuster SJ, Bartlett NL, Assouline S, et al. Mosunetuzumab induces complete remissions in poor prognosis Non-Hodgkin lymphoma patients, including those who are resistant to or relapsing after chimeric antigen receptor T-cell (CAR-T) therapies, and is active in treatment through multiple lines. Blood. 2019;134(Supplement_1):6–6.
   PubMed Web of Science ®Google Scholar
• Budde LE, Ghosh N, Chavez JC, et al. Promising tolerability and efficacy results from dose-escalation in an ongoing phase Ib/II study of mosunetuzumab (M) with polatuzumab vedotin (pola) in patients (pts) with relapsed/refractory (R/R) B-cell non-Hodgkin’s lymphoma (B-NHL). J Clin Oncol. 2021;39(15_suppl):7520–7520.
   Web of Science ®Google Scholar
• Bannerji R, Allan JN, Arnason JE, et al. Odronextamab (REGN1979), a human CD20 x CD3 bispecific antibody, induces durable, complete responses in patients with highly refractory B-Cell Non-Hodgkin lymphoma, including patients refractory to CAR T therapy. Blood. 2020;136(Supplement 1):42–43.
   Google Scholar
• Lugtenburg P, Mous R, Clausen MR, et al. First-in-Human, phase 1/2 trial to assess the safety and clinical activity of subcutaneous GEN3013 (DuoBody®-CD3 × CD20) in B-Cell Non-Hodgkin lymphomas. Blood. 2019;134(Supplement_1):758–758.
   Web of Science ®Google Scholar
• Hutchings M, Mous R, Clausen MR, et al. Dose escalation of subcutaneous epcoritamab in patients with relapsed or refractory B-cell non-Hodgkin lymphoma: an open-label, phase 1/2 study. Lancet. 2021;398(10306):1157–1169.
   PubMed Web of Science ®Google Scholar
• Belada D, Christensen JH, Drott K, et al. Subcutaneous epcoritamab in combination with R-CHOP in patients with previously untreated high-risk diffuse large B-Cell lymphoma: preliminary results from a phase 1/2 trial. Blood. 2021;138(Supplement 1):1413–1413.
   Google Scholar
• Ghosh N, Townsend W, Dickinson M, et al. Glofitamab plus R-CHOP induces high response rates with minimal cytokine release syndrome (CRS) in patients (pts) with relapsed/refractory (R/R) Non-Hodgkin lymphoma (NHL) and previously untreated (1L) diffuse large B-Cell lymphoma (DLBCL): preliminary results from a Dose-Escalation and safety run-in phase Ib study. Blood. 2021;138(Supplement 1):2479–2479.
   Google Scholar
• Dean EA, Mhaskar RS, Lu H, et al. High metabolic tumor volume is associated with decreased efficacy of axicabtagene ciloleucel in large B-cell lymphoma. Blood Adv. 2020;4(14):3268–3276.
   PubMed Web of Science ®Google Scholar
• Kittai AS, Huang Y, Gordon M, et al. Comorbidities predict inferior survival in patients receiving chimeric antigen receptor T cell therapy for diffuse large B cell lymphoma: a multicenter analysis. Transplant Cell Ther. 2021;27(1):46–52.
   PubMedGoogle Scholar
• Garcia-Recio M, Wudhikarn K, Pennisi M, et al. The international prognostic index is associated with outcomes in diffuse large B cell lymphoma after chimeric antigen receptor T cell therapy. Transplant Cell Ther. 2021;27(3):233–240.
   PubMedGoogle Scholar
• Zhou S, Liu M, Ren F, et al. The landscape of bispecific T cell engager in cancer treatment. Biomark Res. 2021;9(1):38.
   PubMed Web of Science ®Google Scholar
• Thieblemont C, Chevret S, Allain V, et al. Lenalidomide enhance CAR T-Cells response in patients with refractory/relapsed large B cell lymphoma experiencing progression after infusion. Blood. 2020;136(Supplement 1):16–17.
   Google Scholar